Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: EZLibra who wrote (2833)	1/6/1999 9:32:00 AM
From: EZLibra	Read Replies (2) \| Respond to of 3702

A layman's explanation of the new patent. Blood vessels are different from normal tissue. New vessels up-regulate signals which induce new growth, unlike mature vessels which are quiescent. However the receptors used in growing the new vessels still exist. Doctor Thorpe targets the dormant receptors. The patent covers anything which targets the receptor and its' ligands, a ligand being a hormone, signal, or any other label. Everything past, present and future used to kill a tumor by destroying the vasculature is covered. Merely shrinking a tumor by shrinking the vasculature is not covered. If you had a choice would you prefer to kill a tumor or treat it the rest of your life? BTW, Phil Thorpe is using coagulation to kill tumors. He only needs to find one receptor in a tumor blood vessel. Then he can create a clotting cascade, induce a massive stroke, and kill the tumor.